Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00274781
Recruitment Status : Completed
First Posted : January 11, 2006
Results First Posted : July 10, 2015
Last Update Posted : July 10, 2015
University of Michigan
National Cancer Institute (NCI)
Information provided by (Responsible Party):
The Cleveland Clinic

January 10, 2006
January 11, 2006
June 3, 2015
July 10, 2015
July 10, 2015
February 2004
December 2008   (Final data collection date for primary outcome measure)
Complete and Partial Remission Per the International Working Group (IWG) Criteria for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) [ Time Frame: at 12 weeks post treatment ]
The null hypothesis to be tested was the percentage who will respond to combination arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) therapy is <10%. A total of >/= 9 responses observed in 30 evaluable patients was taken as evidence warranting further study of the regimen, provided the toxicity profile also appears favorable. The IWG Criteria standardizes the clinical responses in MDS and AML based upon hematologic improvement, quality of life and cytogenic improvement. These standardizations allow for the responses to be determined as either complete responses or partial responses.
Not Provided
Complete list of historical versions of study NCT00274781 on Archive Site
  • Overall Survival [ Time Frame: From date of enrollment to a minimum of three years for survival ]
    Patient's Overall Survival from date of enrollment to a minimum of three years for survival.
  • Tolerability [ Time Frame: 12 Weeks ]
    Tolerability of Therapy was assessed through use of the National Cancer Institute Common Toxicity Criteria (version 3.0). Treatment tolerability was determined based upon whether or not the physician determined therapy was in the patient's best interest, whether the patient wanted to continue therapy or not, whether patients discontinued treatment due to progressive disease, or whether patients discontinued treatment due to toxicity.
Not Provided
Not Provided
Not Provided
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
A Phase II Trial of Combination Therapy With Arsenic Trioxide (Trisenox) and Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Adult Patients With Advanced Myelodysplastic Syndrome

RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving arsenic trioxide together with gemtuzumab ozogamicin works in treating patients with advanced myelodysplastic syndromes.



  • Determine the efficacy of arsenic trioxide and gemtuzumab ozogamicin to achieve complete and partial remissions in patients with advanced myelodysplastic syndromes.


  • Determine the efficacy of this regimen, in terms of 50% decrease in Red Blood Cell (RBC) transfusion requirements and change in hemoglobin concentration from baseline in patients treated with this regimen.
  • Determine the platelet, neutrophil, bone marrow, and cytogenic response in patients treated with this regimen.
  • Determine the response duration in patients treated with this regimen.
  • Determine the quality of life of patients treated with this regimen.
  • Determine the safety and toxicity of this regimen in these patients.

OUTLINE: This is a multicenter, open-label study.

Patients receive arsenic trioxide IV over 1 hour once daily on days 1-5 in week 1 and then twice weekly in weeks 2-12. They also receive gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 12 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, every 12 weeks during study treatment, and then 4 weeks after the completion of study treatment.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Leukemia
  • Myelodysplastic Syndromes
  • Drug: arsenic trioxide
    Arsenic trioxide will be administered at a dose of 0.25 mg/kg/day IV over 1-2 hours for 5 consecutive days during the first week. Subsequently, arsenic trioxide will be given at a dose of 0.25mg/kg/day twice a week for 11 additional weeks (weeks 2-12).
    Other Name: Trisenox
  • Drug: gemtuzumab ozogamicin
    Gemtuzumab ozogamicin consists of a 2 hr infusion at a dose of 3mg/m2 on day 8 of each 12-week cycle. Gemtuzumab ozogamicin should be administered at a minimum of one hour after the completion of the arsenic trioxide infusion
    Other Name: Mylotarg
Experimental: ATO + GO
Arsenic Trioxide 0.25 mg/kg D1-5 Week 1/Twice Weekly W2-12 + Gemtuzumab Ozogamicin 3 mg/m^2 D8 for 1 or 2 Cycles of 12 Weeks each
  • Drug: arsenic trioxide
  • Drug: gemtuzumab ozogamicin
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
November 2010
December 2008   (Final data collection date for primary outcome measure)


  • Diagnosis of one of the following hematologic malignancies:

    • Myelodysplastic syndromes (MDS) of one of the following French-American-British (FAB) classifications:

      • Refractory anemia with excess blasts (RAEB) (WHO RAEB-1)
      • RAEB in transformation (RAEB-t) (RAEB-2)
      • Chronic myelomonocytic leukemia (CMML) with > 5% myeloblasts (WHO CMML-2)
    • International Prognostic Scoring System (IPSS) score of intermediate-2 or higher in the setting of > 5% myeloblasts
    • Acute myeloid leukemia that has evolved from MDS
  • Must not be a candidate for bone marrow transplantation as first-line therapy or must have declined bone marrow transplantation


  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Life expectancy of at least 4 months
  • Serum potassium ≥ 4.0 milliequivalent (mEq/dL) and serum magnesium ≥ 1.8 mg/dL (supplemental electrolytes allowed)
  • Absolute corrected QT interval (QTc) interval < 460 msec
  • No serious medical condition, laboratory abnormality, or psychiatric illness that, in the view of the treating physician, would place the patient at an unacceptable risk if he or she were to participate in the study or would prevent that person from giving informed consent
  • Not pregnant or nursing
  • Fertile patients must be willing to use adequate contraception (barrier method with spermicidal jelly, intrauterine device (IUD), or oral contraceptives)
  • Negative pregnancy test
  • Creatinine > 2.5 mg/dL
  • serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) > 1.5 times upper limit of normal
  • Bilirubin > 2.0 mg/dL
  • No history of malignancy within the past 3 years other than MDS except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast
  • Arsenic trioxide is contraindicated in patients who are hypersensitive to arsenic


  • No prior bone marrow transplantation
  • Must not receive another investigational or approved therapy for MDS within 4 weeks of study enrollment, including growth factors (within 1 week of study enrollment)
  • No prior arsenic trioxide or gemtuzumab ozogamicin
  • No other concurrent cytotoxic drugs or investigational agents
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
P30CA043703 ( U.S. NIH Grant/Contract )
CCF-6818 ( Other Identifier: Cleveland Clinic IRB )
Not Provided
Not Provided
The Cleveland Clinic
The Cleveland Clinic
  • University of Michigan
  • National Cancer Institute (NCI)
Study Chair: Mikkael A. Sekeres, MD, MS The Cleveland Clinic
The Cleveland Clinic
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP